论文部分内容阅读
目的:观察卡培他滨单药一线治疗Ⅱa期老年乳腺癌的临床疗效和不良反应。方法:2002年6月至2005年6月本院收治的71例Ⅱa期老年乳腺癌,患者术后分别行卡培他滨单药口服化疗(X组)及CEF方案化疗(CEF组)。结果:X组3年和5年总生存率分别为97.06%、94.12%,复发及转移率为5.88%,均与CEF组患者无明显差异(P>0.05)。X组具有口服给药的优势,不良反应以手足综合征为主,发生率82.35%,均可耐受,其胃肠道反应以及骨髓抑制程度等均显著低于CEF组(P<0.01),未有因不良反应减量、中断或放弃化疗者,且无明显化疗恐惧感。结论:对于Ⅱa期老年乳腺癌患者术后采用卡培他滨单药口服化疗疗效可靠,给药方便,不良反应极小,患者对治疗的耐受及依从性佳。
Objective: To observe the curative effect and adverse reactions of capecitabine monotherapy first-line treatment of stage Ⅱ a elderly patients with breast cancer. Methods: From June 2002 to June 2005, 71 patients with stage IIa breast cancer were admitted to our hospital. Patients were treated with either capecitabine monotherapy (group X) or CEF chemotherapy (group CEF). Results: The overall 3-year and 5-year overall survival rates in group X were 97.06% and 94.12%, respectively. The recurrence and metastasis rates were 5.88% in X group. There was no significant difference between X group and CEF group (P> 0.05). X group had the advantages of oral administration. Adverse reactions were mainly hand-foot syndrome, the incidence rate was 82.35%, which could be tolerated. The gastrointestinal reaction and the degree of myelosuppression in X group were significantly lower than those in CEF group (P <0.01) No reduction due to adverse reactions, interruption or abandon chemotherapy, and no significant fear of chemotherapy. Conclusion: For stage Ⅱ a elderly patients with breast cancer after capecitabine single oral oral chemotherapy is reliable, convenient administration, minimal adverse reactions, patients with good treatment tolerance and compliance.